Cargando…

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study

BACKGROUND: Insulin glargine (glargine) and insulin NPH (NPH) are two basal insulin treatments. This study investigated the effect on glycaemic control of switching from a NPH-based regimen to a glargine-based regimen in 701 patients with type 1 (n= 304) or type 2 (n= 397) diabetes, using unselected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharplin, Peter, Gordon, Jason, Peters, John R, Tetlow, Anthony P, Longman, Andrea J, McEwan, Philip
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637245/ https://www.ncbi.nlm.nih.gov/pubmed/19152692 http://dx.doi.org/10.1186/1475-2840-8-3

Ejemplares similares

Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis
por: Sharplin, Peter, et al.
Publicado: (2009)

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom
por: Woehl, Anette, et al.
Publicado: (2008)

Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
por: Stürmer, Til, et al.
Publicado: (2013)

Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
por: Lepercq, Jacques, et al.
Publicado: (2012)

Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review
por: Hagenmeyer, Ernst-Günther, et al.
Publicado: (2011)

Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain
por: Delgado, E
Publicado: (2012)

All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
por: Strandberg, Arto Y., et al.
Publicado: (2016)

Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy
por: Dündar, Bumin Nuri, et al.
Publicado: (2009)

A Randomized Clinical Trial of Insulin Glargine and Aspart, Compared to NPH and Regular Insulin in Children with Type 1 Diabetes Mellitus
por: Rostami, Parastoo, et al.
Publicado: (2014)

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus
por: Porcellati, Francesca, et al.
Publicado: (2011)

The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range
por: Elhabashy, Safinaz Adel, et al.
Publicado: (2023)

A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study
por: Gordon, J, et al.
Publicado: (2010)

Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly
por: Varewijck, A. J., et al.
Publicado: (2012)

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
por: Johansen, Odd Erik, et al.
Publicado: (2009)

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes
por: Forst, T, et al.
Publicado: (2010)

Quality of Life of Patients with Type 1 Diabetes Mellitus Using Insulin Analog Glargine Compared with NPH Insulin: A Systematic Review and Policy Implications
por: Almeida, Paulo H. R. F., et al.
Publicado: (2018)

Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus
por: Rys, Przemyslaw, et al.
Publicado: (2015)

Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300 U/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study
por: Wolnik, B., et al.
Publicado: (2022)

Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin
por: Lim, Soo, et al.
Publicado: (2014)

When basal insulin is not enough: A dose–response relationship between insulin glargine 100 units/mL and glycaemic control
por: Umpierrez, Guillermo E., et al.
Publicado: (2019)

Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study
por: Wolnik, B., et al.
Publicado: (2020)

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia
por: Fonseca, V, et al.
Publicado: (2011)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study
por: Rosenstock, J., et al.
Publicado: (2009)

Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis)
por: Roussel, Ronan, et al.
Publicado: (2017)

Insulin glargine/lixisenatide fixed‐ratio combination improves glycaemic variability and control without increasing hypoglycaemia
por: Aronson, Ronnie, et al.
Publicado: (2018)

Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
por: Müller-Wieland, Dirk, et al.
Publicado: (2023)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study
por: Rosenstock, J., et al.
Publicado: (2009)

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes
por: Orchard, Trevor J., et al.
Publicado: (2017)

Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
por: Hartmann, Thorsten, et al.
Publicado: (2016)

Starting bedtime glargine versus NPH insulin in poorly controlled type 2 diabetic patients with various hyperglycemia types (fasting type or postprandial type)
por: Vähätalo, Markku A., et al.
Publicado: (2013)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis
por: Lau, E., et al.
Publicado: (2019)

Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL in Patients with T2D Uncontrolled on NPH or Premixed Insulins as Part of Routine Clinical Practice in Bulgaria: ToUPGRADE Study
por: Kamenov, Zdravko, et al.
Publicado: (2021)

Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes
por: Asias, Bernadette D., et al.
Publicado: (2015)

Study of a New Modified Insulin (Type N.P.H.)
por: Mukherjee, Surath Kumar
Publicado: (1952)

Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice*
por: Hammer, H, et al.
Publicado: (2007)

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
por: Bolli, Geremia B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nljm0ljib1fvermfkc1pm3bt05